会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明授权
    • Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
    • 使用甲磺酸伊马替尼治疗费城阳性白血病的方法
    • US08697702B2
    • 2014-04-15
    • US13129903
    • 2009-11-30
    • Yanfeng WangThea KalebicTimothy P HughesDeborah White
    • Yanfeng WangThea KalebicTimothy P HughesDeborah White
    • A61K31/497
    • A61K31/506
    • The present invention relates to a method of treating Philadelphia-positive leukemia (Ph+ leukemia), in a particular chronic myeloid leukemia (CML), in a human patient population. More specifically, the present invention pertains to a method of treating Ph+ leukemia, such as CML or Phi+ ALL, in a human patient suffering from Ph+ leukemia comprising the steps of (a) administering a predetermined fixed amount of Imatinib as a free base or in the form of a pharmaceutically acceptable salt thereof to the human patient, (b) collecting at least one blood sample from the patient, e.g. within the first 12 months of treatment, (c) determining the plasma trough level (Cmin) of Imatinib, (d) determining the OCT-1 Activity in the blood sample, and (e) adjusting the dose of Imatinib applied to the individual patient in a manner that an Imatinib Cmin value is achieved in the patient of at least 800 ng/mL, if in step (c) an Imatinib Cmin value of less than 800 ng/mL is found and in step (d) an OCT-1 Activity is found below 6.0 to 10.0 ng/200,000 cells.
    • 本发明涉及在人类患者群体中治疗特定慢性骨髓性白血病(CML)中的费城阳性白血病(Ph +白血病)的方法。 更具体地,本发明涉及在患有Ph +白血病的人类患者中治疗Ph +白血病(例如CML或Phi + ALL)的方法,包括以下步骤:(a)施用预定的固定量的伊马替尼作为游离碱或 其药学上可接受的盐的形式提供给人类患者,(b)从患者收集至少一种血液样品, 在治疗的头12个月内,(c)确定伊马替尼的血浆谷值(Cmin),(d)确定血液样品中的OCT-1活性,和(e)调整施用于个体患者的伊马替尼剂量 如果在步骤(c)中发现伊马替尼Cmin值小于800ng / mL,并且在步骤(d)中OCT-1 活性发现低于6.0至10.0ng / 20万个细胞。